Paradigm Biocapital Advisors LP Acquires 100,000 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Paradigm Biocapital Advisors LP raised its position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 13.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 819,660 shares of the company's stock after buying an additional 100,000 shares during the period. Oruka Therapeutics accounts for about 0.6% of Paradigm Biocapital Advisors LP's investment portfolio, making the stock its 27th biggest position. Paradigm Biocapital Advisors LP owned 2.34% of Oruka Therapeutics worth $15,893,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after buying an additional 1,572,853 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Oruka Therapeutics by 2,348.6% in the fourth quarter. Geode Capital Management LLC now owns 342,418 shares of the company's stock worth $6,643,000 after acquiring an additional 328,434 shares during the last quarter. JPMorgan Chase & Co. bought a new position in shares of Oruka Therapeutics in the fourth quarter worth about $54,000. Wellington Management Group LLP raised its stake in shares of Oruka Therapeutics by 15.8% in the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock worth $1,844,000 after acquiring an additional 12,952 shares during the last quarter. Finally, Barclays PLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at $1,446,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Stock Up 0.4%

Shares of Oruka Therapeutics stock traded up $0.04 on Monday, hitting $10.10. The stock had a trading volume of 72,992 shares, compared to its average volume of 227,285. Oruka Therapeutics, Inc. has a twelve month low of $5.49 and a twelve month high of $31.13. The business's 50 day moving average is $9.86 and its two-hundred day moving average is $14.68. The stock has a market cap of $378.15 million, a price-to-earnings ratio of -1.61 and a beta of 0.25.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. As a group, equities analysts predict that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ORKA shares. Wolfe Research started coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, February 7th. Finally, Wedbush reissued an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Thursday. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $39.86.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.